

JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination [Retraction]

Zhang H, Zhao H, He X, Xi F, Liu J. *Cancer Manag Res.* 2020;12:9813–9824.

We, the Editor and Publisher of the journal *Cancer Management and Research* are retracting the published article.

Following publication of the article, concerns were raised regarding the duplication of images from Figures 2, 4 and 5 with images from unrelated articles. Specifically,

- The images for Figure 2J, Mock, BB-z and δ IL2RBB-z have been duplicated with the images for Figure 3G, UTD, 20min; EGFR-CAT T, 4h and EGFR-CAR T, 12h, respectively from Li H, Huang Y, Jiang DQ, et al. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. *Cell Death Dis.* 2018;9:177. <https://doi.org/10.1038/s41419-017-0238-6>.
- The images for Figure 4A, have been duplicated with the images for Figure 6E from Mohammed S, Sukumaran S, Bajgain P, et al. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. *Molecular Therapy.* 2017;25;(1):249–258. <https://doi.org/10.1016/j.ymthe.2016.10.016>.
- The images for Figure 5A, have been duplicated with the images for Figure 6E, PBS and Anti-control, ZO-1, from Zhou W, Fong MY, Min Y, et al. Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. *Cancer Cell.* 2014;25(4):501–515. <https://doi.org/10.1016/j.ccr.2014.03.007>.

The corresponding author did not respond to our queries and was unable to provide a satisfactory explanation for how the images came to be duplicated or provide satisfactory original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the Publisher and Editor requested to retract the article and the corresponding author was notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Cancer Management and Research

Dovepress

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

<https://doi.org/10.2147/CMAR.S483243>

Cancer Management and Research 2024;16 641

641

Received: 18 June 2024
Accepted: 18 June 2024
Published: 20 June 2024



© 2024 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).